These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Reimbursement for thrombectomy devices in patients who are ineligible for intravenous tissue-type plasminogen activator. Broderick JP; Tomsick TA; Stroke; 2013 May; 44(5):1215-6. PubMed ID: 23598521 [No Abstract] [Full Text] [Related]
23. [Antithrombotic and thrombolytic treatments: current concepts from the North American guidelines and French practice]. J Mal Vasc; 2005 Sep; 30 Spec No 2():2S8-2S79. PubMed ID: 16392541 [No Abstract] [Full Text] [Related]
24. Emergent decision-making: defining the patient perspective. Knudtson ML Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261 [No Abstract] [Full Text] [Related]
25. Critical concepts in cost-effectiveness for cardiovascular specialists. Califf RM; Eisenstein EL Am Heart J; 2000 Dec; 140(6 Suppl):S143-7. PubMed ID: 11100008 [No Abstract] [Full Text] [Related]
26. [Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]. Leschke M; Schoebel FC; Strauer BE Internist (Berl); 1996 Jun; 37(6):597-606. PubMed ID: 8767992 [No Abstract] [Full Text] [Related]
28. Thrombolytic therapy with alteplase for ischaemic stroke. Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701 [TBL] [Abstract][Full Text] [Related]
29. The development of thrombolytic therapy. Sherry S J Am Coll Cardiol; 1987 Oct; 10(4):933-4. PubMed ID: 3655157 [No Abstract] [Full Text] [Related]
30. Thrombolytic therapy. Young GP; Hoffman JR Emerg Med Clin North Am; 1995 Nov; 13(4):735-58. PubMed ID: 7588187 [TBL] [Abstract][Full Text] [Related]
31. Is intensive drug therapy appropriate for older patients? Gollub SB Lancet; 1999 Mar; 353(9157):940-1. PubMed ID: 10459896 [No Abstract] [Full Text] [Related]
32. Coronary thrombolytic therapy: state of the art. Marx M; Levin DC AJR Am J Roentgenol; 1986 Jul; 147(1):1-8. PubMed ID: 3521234 [TBL] [Abstract][Full Text] [Related]
33. On equivalence. Malik P Can J Cardiol; 2003 Aug; 19(9):992. PubMed ID: 12915924 [No Abstract] [Full Text] [Related]
34. [Use of the new thrombolytic substance plasmakinase to treat acute experimental coronary artery thrombosis]. Khvatov VB; Galankina IE; Maksimovich IV Grudn Khir; 1983; (4):22-32. PubMed ID: 6354883 [No Abstract] [Full Text] [Related]
35. [Treatment of patients with acute coronary insufficiency with thrombolytic preparations (fibrinolysin and thrombolytin)]. Khalfen ESh; Orlova NP Ter Arkh; 1968 Dec; 40(12):48-52. PubMed ID: 4247402 [No Abstract] [Full Text] [Related]
36. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction. Becker RC Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769 [TBL] [Abstract][Full Text] [Related]
37. [Thrombolytic therapy in myocardial infarction and older patients]. Müller-Ehmsen J Dtsch Med Wochenschr; 2001 Sep; 126(38):1058-9. PubMed ID: 11565061 [No Abstract] [Full Text] [Related]
40. Fibrinolytic activity in coronary artery disease and myocardial infarction, and the role of fibrinolytic therapy in coronary thrombosis. Menon IS Lab Pract; 1968 May; 17(5):592-4. PubMed ID: 5648576 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]